APEX Study Phase 1b Results on KSI-101 for Macular Edema
This document presents the 24-week results from the Phase 1b APEX study evaluating KSI-101 in patients with macular edema secondary to inflammation.
Bispecific trap-antibody inhibiting interleukin-6 and vascular endothelial growth factor (KSI-101): Week 24 Results From the Phase 1b APEX Study in Patients with Macular Edema Secondary to Inflammation (MESI) Dolly Chang 1 ; Allen Hu 2 ; Charles Wykoff 3 ; David Almeida 4 ; Melina Cavichini Cordeiro 1 , Scott Fitzpatrick 1 ; Victor Perlroth 1 ; J. Pablo Velazquez-Martin 1 1 Kodiak Sciences, Palo Alto, United States; 2 Cumberland Valley Retina Consultants, Hagerstown, US; 3 Blanton Eye Institute, Houston, US; 4 Erie Retina Research, Erie, US, 5 Retina Consultants Medical Group, Sacramento, US. Relevant Financial Disclosures: Funding: K23EY032990, R21EY034543, R01EY037916. Consultant: Kowa, Oculis, ANI Pharmaceuticals, AstraZeneca, AbbVie, Alfasigma, Kodiak Sciences, Genentech Edmund Tsui, MD Associate Professor of Ophthalmology, Stein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles (UCLA), USA On behalf of the APEX Study Group
APEX Study Phase 1b Results on KSI-101 for Macular Edema Page 2